Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication
- 1 December 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 18 (12) , 1942-1947
- https://doi.org/10.1161/01.atv.18.12.1942
Abstract
—Cilostazol is an antiplatelet agent and vasodilator marketed in Japan for treatment of ischemic symptoms of peripheral vascular disease. It is currently being evaluated in the United State...Keywords
This publication has 17 references indexed in Scilit:
- Involvement of the Rapid Increase in cAMP Content in the Vanadate-Stimulated Release of Lipoprotein Lipase Activity from Rat Fat Pads.Biological & Pharmaceutical Bulletin, 1996
- Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP‐dependent protein kinasesEuropean Journal of Clinical Investigation, 1994
- CilostazolCardiovascular Drug Reviews, 1993
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993
- The Relationship between Ankle-Arm Index and Mortality in Older Men and WomenJournal of the American Geriatrics Society, 1993
- Mortality over a Period of 10 Years in Patients with Peripheral Arterial DiseaseNew England Journal of Medicine, 1992
- SERUM HIGH-DENSITY LIPOPROTEINS IN PERIPHERAL VASCULAR DISEASEThe Lancet, 1978
- Intermittent claudication: prevalence and risk factors.BMJ, 1978
- SERUM LIPIDS AND LIPOPROTEINS IN PERIPHERAL VASCULAR DISEASEThe Lancet, 1971
- Sur un dosage rapide du cholesterol lié aux α-et aux β-lipoprotéines du sérumClinica Chimica Acta; International Journal of Clinical Chemistry, 1960